CRISPR Therapeutics AG（CRSP）作为基因编辑领域的先锋企业，前景相当广阔。从技术上看，其CRISPR/Cas9技术精准度高，脱靶率极低，递送系统创新还降低了成本，提升治疗可及性。首款获批药物Casgevy成功商业化，填补了医疗空白，后续还有肿瘤免疫、遗传性眼病等临床前项目在推进。从市场层面，全球基因编辑市场增长迅猛，潜在患者群体庞大，加上AI辅助加速开发，都为CRSP提供了有利环境 。尽管面临技术安全性、财务压力和政策监管等风险，但凭借技术优势和市场潜力，一旦攻克难关，有望在基因编辑市场大放异彩，值得投资者持续关注。
| Side | Price | Filled | Realized P&L |
|---|---|---|
| Sell Open | 0.25 2Lot(s) | -- Closed |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- AL_Ishan·2025-07-17强，感谢推荐LikeReport